Regulatory Story

RNS Number : 7502U
Shield Therapeutics PLC
01 April 2019
 

Shield Therapeutics plc

("Shield" or the "Group")

 

Additional listing

 

London, UK, 1 April 2019: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that it issued and allotted 268,196 Ordinary Shares of 1.5p each on 21 February 2019 following the exercise of options under the Shield Therapeutics plc 2016 Company Share Option Plan.

 

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 5 April 2019. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

 

Following admission, the Company's issued share capital will comprise 116,694,047 Ordinary Shares and each Ordinary Share carries one vote.  There are no Ordinary Shares held in treasury and accordingly, the total number of voting rights is 116,694,047. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

- Ends -

 

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Carl Sterritt, Chief Executive Officer

+44 (0)20 7186 8500

Tim Watts, Chief Financial Officer

 

 

 

Nominated Advisor and Broker

 

Peel Hunt LLP

 

James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

 

 

Financial PR & IR Advisor

 

Walbrook PR

+44 (0)20 7933 8780 or shield@walbrookpr.com

Paul McManus / Helen Cresswell

+44 (0)7980 541 893 / +44 (0)7841 917 679

 

 

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.  Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.  For more information please visit www.shieldtherapeutics.com. 

 

 

 

 

1 - https://www.shieldtherapeutics.com/rns_news/positive-results-for-feraccru-in-aegis-h2h-study/ 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSDMGGDVMGGLZM